Illumina, Inc.

ILMN

US4523271090

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 16:00:00 2025-06-23 EDT			5-day change	1st Jan Change
90.61 ^USD	+0.13%		+0.40%	-32.19%

06-23	Illumina, Inc. entered into an agreement to acquire SomaLogic, Inc. from Standard BioTools Inc. for approximately $430 million.	CI
06-23	Illumina Signs Deal With Standard BioTools to Acquire SomaLogic	MT

Illumina to Record $1.47 Goodwill Impairment Charge in Q2 After Grail Spin-Off

Published on 2024-06-28 at 07:02, updated on 2024-06-28 at 07:03

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Illumina, Inc.

Illumina, Inc. entered into an agreement to acquire SomaLogic, Inc. from Standard BioTools Inc. for approximately $430 million.	06-23	CI
Illumina Signs Deal With Standard BioTools to Acquire SomaLogic	06-23	MT
Illumina, Inc., Q1 2025 Earnings Call, May 08, 2025	06-17
Saudi Arabia Signs Multiple Healthcare Deals, Partnerships at BIO 2025	06-17	MT
Illumina Inc. Unveils PromoterAI, Groundbreaking Algorithm to Accelerate Insights for Rare Disease Diagnosis	05-29	CI
Illumina, Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-28-2025 02:30 PM	05-28
Illumina Expands Clinical Oncology Portfolio Unlocking New Standard of Care and Access to Precision Therapies	05-28	CI
Illumina Expands Clinical Oncology Portfolio Unlocking New Standard Of Care And Access To Precision Therapies	05-28	RE
Pillar Biosciences Inc. announced that it has received $34.5 million in funding from Illumina, Inc., Soleus Capital Management, L.P. and other investors	05-26	CI
UBS Adjusts Price Target on Illumina to $98 From $145, Maintains Neutral Rating	05-14	MT
Illumina Inc. Announces the Launch of DRAGEN Version 4.4 Software (v4.4)	05-13	CI
Illumina Faces Uncertainties From China Ban, Research Slump, Morgan Stanley Says	05-12	MT
Morgan Stanley Adjusts Illumina Price Target to $100 From $136, Maintains In Line Rating	05-12	MT
Illumina Q1 Non-GAAP Earnings, Revenue Decline; Reduces Full Year Guidance	05-08	MT
Earnings Flash (ILMN) ILLUMINA INC. Reports Q1 Adjusted EPS $0.97, vs. FactSet Est of $0.93	05-08	MT
Earnings Flash (ILMN) ILLUMINA INC. Reports Q1 Revenue $1.04B, vs. FactSet Est of $1.02B	05-08	MT
Tranche Update on Illumina, Inc.'s Equity Buyback Plan announced on November 6, 2024.	05-08	CI
Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2025	05-08	CI
Illumina, Inc. Reports Earnings Results for the First Quarter Ended March 30, 2025	05-08	CI
Illumina Partners With Ovation.io to Create GLP-1 Dataset for Drug Discovery	05-01	MT
Illumina, Inc. and Ovation.io Launches First-Of-Kind GLP-1 Dataset to Accelerate New Therapy Development	05-01	CI
Pillar Biosciences Inc. announced that it expects to receive $16.484987 million in funding	04-28	CI
Analyst recommendations: Airbnb, Alphabet, Nvidia, Hyatt Hotels, Lululemon…	04-16
Illumina, Tempus AI Collaborating to Accelerate Clinical Use of Sequencing Tests	04-15	MT
Illumina And Tempus Partner To Drive The Future Of Precision Medicine Through Genomic Ai Innovation	04-15	RE

Illumina, Inc. is engaged in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Its products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its product categories include Instruments, Kits & Reagents, Selection Tools, and Software & Analysis. Its Instruments category include sequencing platforms, microarray scanners, and IVD instruments. Its Kits & Reagents category consists of library preparation kits, sequencing reagents, microarray kits, clinical research products, and IVD products. Its Selection Tools category include Library Prep & Array Kit Selector, Gene Panel & Array Finder, DesignStudio Custom Assay Designer, and other. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training. It is also a developer of an emerging and highly differentiated single-cell technology.

Employees

9,000

Sector

Advanced Medical Equipment & Technology

Calendar

08-06 - Q2 2025 Earnings Release (Projected)

More about the company